false
Catalog
AJSP2402 - CME/CMLE - CME/CMLE - Current gross exa ...
Current gross examination and reporting patterns o ...
Current gross examination and reporting patterns of post–neoadjuvant chemotherapy cystectomy specimens
Back to course
Pdf Summary
The article discusses the need for a standardized approach in the gross examination and reporting of post-neoadjuvant chemotherapy (NACT) cystectomy specimens for bladder cancer. Neoadjuvant chemotherapy is often used for muscle-invasive bladder cancer, leading to cases where no gross lesions are identifiable post-treatment. The study surveyed pathologists and pathologists' assistants to evaluate current practices and found inconsistencies, especially when no gross lesions were present. The majority of respondents supported the implementation of standardized protocols to address these inconsistencies.<br /><br />Key findings include that identifying gross tumors occurred less frequently than identifying tumor beds or ulcer beds. Respondents typically recommended submitting gross tumor in 1 block per centimeter and tumor beds entirely. However, there was more variability in handling cases with no gross lesions. Pathologists and PAs generally agreed on practices when gross lesions were present but differed in approaches for cases without gross lesions.<br /><br />The study highlights the importance of addressing the lack of standardization in the examination and reporting of post-NACT cystectomy specimens. It emphasizes the need for guidelines to streamline practices and improve the consistency of handling these challenging cases. Overall, the majority of respondents expressed support for implementing a standardized approach to gross examination and reporting for post-NACT cystectomy specimens.
Keywords
Standardized approach
Gross examination
Post-neoadjuvant chemotherapy
Cystectomy specimens
Bladder cancer
Pathologists
Pathologists' assistants
Inconsistencies
Standardized protocols
Gross lesions
×
Please select your language
1
English